Establishment of a Model for Predicting Induction Dose of Remazolam in Painless Gastroscopy Based on Machine Learning Algorithm

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200066628

Enrollment

Unknown

Registered

2022-12-12

Start date

2022-12-15

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Painless Gastroscopy

Interventions

Patients receiving painless gastroscopy:Remazolam for sedation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients undergoing painless gastroscopy 2.people aged 18 and over 3.ASA classification ?-? 4.Fully informed and signed informed consent

Exclusion criteria

Exclusion criteria: 1. Difficulty in communication 2. There are contraindications to anesthesia or allergy to anesthetic drugs 3. Patients with recent upper respiratory tract infection

Design outcomes

Primary

Measure	Time frame
Total dosage of ramazolam for successful gastroscopic implantation;Times of addition of ramazolam;	—

Secondary

Measure	Time frame
Adverse respiratory events (respiratory depression, hypoxemia);Other adverse events (cough, burp, injection pain);	—

Countries

China

Contacts

Public ContactHaoqian

The Second Hospital of Jiaxing

460274334@qq.com13758364510

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026